This article is more than 5 years old. Information may no longer be current.

ENDEAVOR IV

Randomized Comparison of Zotarolimus-Eluting and Paclitaxel-Eluting Stents in Patientswith Coronary Artery Disease

Issue: March 2010

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Trial assessed 12-month safety and efficacy of zotarolimus-eluting stent vs. paclitaxeleluting stent in patients with single de novo coronary lesions.

Design: prospective, randomized, controlled
Patients: 1,548
Centers: multicenter
Country: United States

RESULTS: Target vessel failure at nine months was similar between the zotarolimus and the paclitaxel groups (6.6% vs. 7.1%; P<.001 for noninferiority). There were no significant differences at nine and 12 months between study groups for death, cardiac death, MI and major adverse cardiac events. There were also no differences at nine and 12 months in overall clinically driven target lesion revascularization or target vessel revascularization. There were fewer periprocedural non–Q-wave MI with the zotarolimus-eluting stent vs. the paclitaxeleluting stent (0.5% vs. 2.2%; P=.007).

Published in: J Am Coll Cardiol. 2010;55:543-554.

Click here to read more about the ENDEAVOR IV trial.